標(biāo)題: Titlebook: Current and Emerging Therapies in Pancreatic Cancer; Tanios Bekaii-Saab,Bassel El-Rayes Book 2018 Springer International Publishing AG 201 [打印本頁] 作者: 警察在苦笑 時(shí)間: 2025-3-21 17:01
書目名稱Current and Emerging Therapies in Pancreatic Cancer影響因子(影響力)
書目名稱Current and Emerging Therapies in Pancreatic Cancer影響因子(影響力)學(xué)科排名
書目名稱Current and Emerging Therapies in Pancreatic Cancer網(wǎng)絡(luò)公開度
書目名稱Current and Emerging Therapies in Pancreatic Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Current and Emerging Therapies in Pancreatic Cancer被引頻次
書目名稱Current and Emerging Therapies in Pancreatic Cancer被引頻次學(xué)科排名
書目名稱Current and Emerging Therapies in Pancreatic Cancer年度引用
書目名稱Current and Emerging Therapies in Pancreatic Cancer年度引用學(xué)科排名
書目名稱Current and Emerging Therapies in Pancreatic Cancer讀者反饋
書目名稱Current and Emerging Therapies in Pancreatic Cancer讀者反饋學(xué)科排名
作者: MAIM 時(shí)間: 2025-3-21 22:29 作者: OTTER 時(shí)間: 2025-3-22 01:31
Pathology: Premalignant and Malignant Diseases and Molecular Genetics, radiological and macroscopic findings are presented, to correlate with the detailed microscopic findings. Several illustrative gross photos, microphotographs, and tables are included. Most common hereditary syndromes and their associated risks for pancreatic cancer are listed. Molecular genetics of作者: 閑逛 時(shí)間: 2025-3-22 05:39
Screening for Pancreatic Cancer: Who to Screen and How to Follow-Up?,ase biomarker. Therefore, screening patients at increased risk for pancreatic cancer is currently the favored strategy. This approach involves careful assessment of a patient’s family history and genetic profile as well as other nongenetic risk factors. Screening is typically offered to those with a作者: 暫時(shí)過來 時(shí)間: 2025-3-22 10:13
Staging and Prognostic Implications,e mainstay curative approach, but only one-fifth of the patients after pancreatic resection are alive at 5?years. Two different staging systems have been developed that help in determining prognosis and therapeutic strategy. TNM staging proposed by the American Joint Committee on Cancer (AJCC) divid作者: 讓你明白 時(shí)間: 2025-3-22 14:18 作者: 讓你明白 時(shí)間: 2025-3-22 18:31
Imaging of Pancreatic Malignancies,y ductal system and the pancreas including mass lesions. MRI is highly accurate for identification and staging of pancreatic ductal adenocarcinoma. MRI can differentiate adenocarcinoma from other solid and cystic pancreatic lesions including neuroendocrine tumor, cystic neoplasms, and intraductal pa作者: defuse 時(shí)間: 2025-3-22 22:34
Advanced Endoscopic Procedures,tent placement have a very central and important role in the diagnosis, treatment, and palliation of patients with pancreatic cancer. They are used as part of a multidisciplinary management approach which also includes both radiologic and surgical approaches to management of patients with pancreatic作者: 陪審團(tuán) 時(shí)間: 2025-3-23 05:19 作者: 赦免 時(shí)間: 2025-3-23 07:29
The Management of Locally Advanced Nonmetastatic Pancreas Cancer,e remaining 30–40% of patients present with borderline resectable (BR) or locally advanced unresectable pancreatic cancer (LAPC). Recently endorsed by the NCCN, the Intergroup definition of BR and LAPC has been developed to promote multicenter collaboration and to standardize future clinical trials.作者: 凹槽 時(shí)間: 2025-3-23 12:39
Cytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed,poor outcomes despite recent advances in chemotherapeutic approaches. Gemcitabine therapy has been the standard first-line treatment for patients with unresectable locally advanced or metastatic pancreatic cancer until recent studies showed improved outcomes with chemotherapy combinations, albeit wi作者: curriculum 時(shí)間: 2025-3-23 16:30 作者: PAC 時(shí)間: 2025-3-23 19:59 作者: 盡管 時(shí)間: 2025-3-24 02:07
Synthetic Lethality: Achilles Heel in Select Patient Subpopulations,re one such event is survivable. Mutations in BRCA1/2 or homologous recombination genes lead to dependency on alternative low-fidelity DNA repair mechanisms. Inhibition of the alternative pathways, such as with a PARP inhibitor, can lead to cancer cell death in preclinical models..Up to 15% of pancr作者: blight 時(shí)間: 2025-3-24 03:14
Immunotherapies in Pancreatic Cancer,hus, most of the focus has been on implementing new drugs and therapeutic approaches in the metastatic setting. As the effect of cytotoxic agents has plateaued, immunotherapeutic interventions have emerged, in an attempt to improve the prognosis in this dismal disease. A better understanding of the 作者: 新手 時(shí)間: 2025-3-24 09:45
Vaccine Therapy in Pancreatic Cancer,the armamentarium of therapeutics for this disease. Vaccines represent an important method to train the body’s own immune system to attack pancreatic cancer cells. Despite a number of unique targets on pancreatic cancer cells, vaccines have been largely ineffective at prolonging survival in pancreat作者: Plaque 時(shí)間: 2025-3-24 11:54 作者: macrophage 時(shí)間: 2025-3-24 15:33 作者: 過度 時(shí)間: 2025-3-24 22:12
The Role for Palliative Surgical Interventions in Pancreatic Cancer,patients present with biliary obstruction, gastric outlet obstruction, and malignant bowel obstruction secondary to tumor burden and local invasion. While surgery has been utilized liberally to treat these conditions, more recent evidence emphasizing palliation, decreased hospital length of stay, an作者: pessimism 時(shí)間: 2025-3-24 23:37
https://doi.org/10.1007/978-3-319-58256-6cystic pancreatic lesions; resectable disease; non-metastatic disease; cytotoxic therapy; JAK/Stat pathw作者: 材料等 時(shí)間: 2025-3-25 06:19 作者: 盲信者 時(shí)間: 2025-3-25 10:36 作者: 遺傳 時(shí)間: 2025-3-25 11:40
http://image.papertrans.cn/d/image/241495.jpg作者: boisterous 時(shí)間: 2025-3-25 17:45 作者: 啞巴 時(shí)間: 2025-3-25 21:32
https://doi.org/10.1007/978-3-663-04516-8 procedures with curative intent become increasingly more common. Anatomic variations of the pancreatobiliary tree and its vasculature are exceedingly common. Precise knowledge of the relevant anatomy is of utmost significance both for diagnosis and interventional treatment of such diseases. In this作者: Biomarker 時(shí)間: 2025-3-26 00:59
https://doi.org/10.1007/978-3-663-04516-8 radiological and macroscopic findings are presented, to correlate with the detailed microscopic findings. Several illustrative gross photos, microphotographs, and tables are included. Most common hereditary syndromes and their associated risks for pancreatic cancer are listed. Molecular genetics of作者: Prologue 時(shí)間: 2025-3-26 06:35
https://doi.org/10.1007/978-3-663-04957-9ase biomarker. Therefore, screening patients at increased risk for pancreatic cancer is currently the favored strategy. This approach involves careful assessment of a patient’s family history and genetic profile as well as other nongenetic risk factors. Screening is typically offered to those with a作者: eucalyptus 時(shí)間: 2025-3-26 12:13
https://doi.org/10.1007/978-3-663-04960-9e mainstay curative approach, but only one-fifth of the patients after pancreatic resection are alive at 5?years. Two different staging systems have been developed that help in determining prognosis and therapeutic strategy. TNM staging proposed by the American Joint Committee on Cancer (AJCC) divid作者: 生命層 時(shí)間: 2025-3-26 14:29 作者: 無能性 時(shí)間: 2025-3-26 19:08
https://doi.org/10.1007/978-3-663-04965-4y ductal system and the pancreas including mass lesions. MRI is highly accurate for identification and staging of pancreatic ductal adenocarcinoma. MRI can differentiate adenocarcinoma from other solid and cystic pancreatic lesions including neuroendocrine tumor, cystic neoplasms, and intraductal pa作者: seduce 時(shí)間: 2025-3-27 00:06 作者: 厚顏無恥 時(shí)間: 2025-3-27 02:27 作者: poliosis 時(shí)間: 2025-3-27 08:36
https://doi.org/10.1007/978-3-663-05134-3e remaining 30–40% of patients present with borderline resectable (BR) or locally advanced unresectable pancreatic cancer (LAPC). Recently endorsed by the NCCN, the Intergroup definition of BR and LAPC has been developed to promote multicenter collaboration and to standardize future clinical trials.作者: 彩色 時(shí)間: 2025-3-27 09:31
https://doi.org/10.1007/978-3-663-05139-8poor outcomes despite recent advances in chemotherapeutic approaches. Gemcitabine therapy has been the standard first-line treatment for patients with unresectable locally advanced or metastatic pancreatic cancer until recent studies showed improved outcomes with chemotherapy combinations, albeit wi作者: 果核 時(shí)間: 2025-3-27 14:47
https://doi.org/10.1007/978-3-663-05140-4arly targeted drugs that have demonstrated activity in pancreatic cancer. Randomized clinical trials have evaluated agents targeting cellular signaling pathways (EGFR, MUC1, farnesyl transferase, HIF1-α, MAPK, JAK, and sonic hedgehog), angiogenesis (VEGF, VEGFR), and stromal remodeling (matrix metal作者: FAZE 時(shí)間: 2025-3-27 21:10
https://doi.org/10.1007/978-3-663-05746-8omponents, including fibroblasts, pancreatic stellate cells, immune cells, blood vessels, and extracellular matrix, that in concert form a dense stromal compartment characteristic of pancreatic tumors. In this chapter, we will review the function of, and interaction between, the primary elements of 作者: Locale 時(shí)間: 2025-3-28 01:30
https://doi.org/10.1007/978-3-663-05746-8re one such event is survivable. Mutations in BRCA1/2 or homologous recombination genes lead to dependency on alternative low-fidelity DNA repair mechanisms. Inhibition of the alternative pathways, such as with a PARP inhibitor, can lead to cancer cell death in preclinical models..Up to 15% of pancr作者: 窒息 時(shí)間: 2025-3-28 03:12
https://doi.org/10.1007/978-3-663-05746-8hus, most of the focus has been on implementing new drugs and therapeutic approaches in the metastatic setting. As the effect of cytotoxic agents has plateaued, immunotherapeutic interventions have emerged, in an attempt to improve the prognosis in this dismal disease. A better understanding of the 作者: 來這真柔軟 時(shí)間: 2025-3-28 09:17
https://doi.org/10.1007/978-3-663-05746-8the armamentarium of therapeutics for this disease. Vaccines represent an important method to train the body’s own immune system to attack pancreatic cancer cells. Despite a number of unique targets on pancreatic cancer cells, vaccines have been largely ineffective at prolonging survival in pancreat作者: BADGE 時(shí)間: 2025-3-28 10:59
Erweiterung des Befundspektrums,or genetically modified viruses, have the potential to selectively replicate in tumor cells and induce apoptosis without harming the surrounding normal tissue, thus representing an innovative and intriguing treatment option against pancreatic cancer. Herein, we will highlight and review the role of 作者: Glutinous 時(shí)間: 2025-3-28 14:41
Eine Druckformatvorlage definierenmotherapy and radiation for all stages of disease. This was delivered over 5–6?weeks and given concurrently with 5-fluorouracil or gemcitabine. While this approach has been effective at improving local control and pain, adjacent dose-limiting structures such as the stomach and bowel precluded achiev作者: 暴發(fā)戶 時(shí)間: 2025-3-28 19:18 作者: custody 時(shí)間: 2025-3-29 01:00 作者: 帶來 時(shí)間: 2025-3-29 03:22 作者: incite 時(shí)間: 2025-3-29 09:43
https://doi.org/10.1007/978-3-663-04960-9 implications for surgical interventions and clinical outcomes. Varied definitions from different medical societies are utilized for classifying patients into clinical groups. Recently, there has been attempt to standardize the definition of resectable, borderline resectable, and locally advanced pa作者: aphasia 時(shí)間: 2025-3-29 11:49
https://doi.org/10.1007/978-3-663-04963-0hermore, “l(fā)iquid biopsies” may allow monitoring circulating tumor DNA and circulating tumor cells during therapy. However, to this date, CA 19-9 remains the only FDA-approved biomarker for use in the clinic.作者: 按等級 時(shí)間: 2025-3-29 16:12
https://doi.org/10.1007/978-3-663-05130-5ch are addressed. No major difference in outcome has been shown with any of the above changes in technique. While current recommendations are for patients with resectable disease to undergo resection unless enrolled in a neoadjuvant therapy trial, most pancreatic surgeons will agree that once a tole作者: Oration 時(shí)間: 2025-3-29 23:11 作者: 粘連 時(shí)間: 2025-3-30 03:03 作者: 向前變橢圓 時(shí)間: 2025-3-30 04:14
,Theorie über die Reduktion von Eisenerzen,o proven useful in improving nausea and vomiting in the setting of malignant bowel obstruction. Although some promising developments for treatment of locally advanced disease in the form of irreversible electroporation (IRE) have been proposed, these interventions are still in their early stages of 作者: 不可知論 時(shí)間: 2025-3-30 09:11 作者: 圣人 時(shí)間: 2025-3-30 15:25
Staging and Prognostic Implications, implications for surgical interventions and clinical outcomes. Varied definitions from different medical societies are utilized for classifying patients into clinical groups. Recently, there has been attempt to standardize the definition of resectable, borderline resectable, and locally advanced pa作者: meritorious 時(shí)間: 2025-3-30 17:09 作者: cinder 時(shí)間: 2025-3-30 21:50 作者: 諷刺 時(shí)間: 2025-3-31 00:55
The Management of Locally Advanced Nonmetastatic Pancreas Cancer,.Upon completion of NT, the decision to proceed with resection has traditionally been determined by radiologic imaging. However, radiologic response is not an accurate predictor of resectability, and all patients should undergo an attempt at resection after NT, in the absence of systemic progression作者: Gleason-score 時(shí)間: 2025-3-31 08:33
Novel Radiotherapy Modalities,SBRT), and heavy ion (proton) therapy. Now radiation therapy can be delivered much more precisely over 1–3?weeks and more easily combined with novel systemic therapies, targeted therapies, and immunotherapy. In addition, next-generation sequencing and imaging biomarkers can be used to better identif作者: 期滿 時(shí)間: 2025-3-31 10:37 作者: 華而不實(shí) 時(shí)間: 2025-3-31 16:05 作者: DEMUR 時(shí)間: 2025-3-31 20:43 作者: 小畫像 時(shí)間: 2025-4-1 00:13
Anatomy of the Pancreas and Biliary Tree, chapter we outline the embryological development of the hepatobiliary tree and pancreas and describe the pertinent surgical anatomy with emphasis on frequently occurring variants that must be anticipated in order to prevent unnecessary complications.作者: Interlocking 時(shí)間: 2025-4-1 02:53 作者: paltry 時(shí)間: 2025-4-1 08:23
Immunotherapies in Pancreatic Cancer,microenvironment in pancreatic cancer has led to identifying multiple immunological targets that are currently under investigation. In this chapter, we focus on immunotherapies that are being investigated in pancreatic cancer.作者: 簡潔 時(shí)間: 2025-4-1 13:25
ed with implementing new pancreatic cancer treatments.WritteThis book provides a comprehensive, state-of-the art review of current and new therapies in treating pancreatic cancer. In addition to discussing the current landscape for treating various stages of pancreatic cancer, the text highlights se作者: dictator 時(shí)間: 2025-4-1 15:10
https://doi.org/10.1007/978-3-663-04965-4I can differentiate adenocarcinoma from other solid and cystic pancreatic lesions including neuroendocrine tumor, cystic neoplasms, and intraductal papillary mucinous cystadenoma (IPMN). The MRI appearance of the common cystic and solid primary pancreatic neoplasms will be reviewed along with technical considerations of pancreas MRI.作者: Amnesty 時(shí)間: 2025-4-1 18:35 作者: Water-Brash 時(shí)間: 2025-4-2 02:20
Erweiterung des Befundspektrums,l tissue, thus representing an innovative and intriguing treatment option against pancreatic cancer. Herein, we will highlight and review the role of oncolytic viral therapy in pancreatic cancer while discussing its limitations and potential alternatives to improve its treatment efficacy against this disease.作者: placebo-effect 時(shí)間: 2025-4-2 06:29 作者: calorie 時(shí)間: 2025-4-2 09:09
Imaging of Pancreatic Malignancies,I can differentiate adenocarcinoma from other solid and cystic pancreatic lesions including neuroendocrine tumor, cystic neoplasms, and intraductal papillary mucinous cystadenoma (IPMN). The MRI appearance of the common cystic and solid primary pancreatic neoplasms will be reviewed along with technical considerations of pancreas MRI.作者: Commonplace 時(shí)間: 2025-4-2 14:59
Advanced Endoscopic Procedures, part of a multidisciplinary management approach which also includes both radiologic and surgical approaches to management of patients with pancreatic cancer. This chapter will review the role of these advanced endoscopic procedures in pancreatic cancer.
